Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SAN DIEGO, Feb. 27, 2018 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its fourth quarter and full year 2017 financial results after the market closes on Tuesday, March 13, 2018 followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review financial results and discuss other business matters.
The conference call dial-in numbers are (855) 765-5682 for domestic callers and (919) 825-3204 for international callers. The conference ID number for the call is 7392256. Participants may access the live webcast via a link on the Vital Therapies website in the Investors Relations section under Events at: http://ir.vitaltherapies.com/. The webcast will be archived on the Company's website shortly after completion of the call.
For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 7:30 p.m. ET on March 13, 2018 to 7:30 p.m. ET on March 20, 2018. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 7392256.
Upcoming Investor Conference
Additionally, the Company will be presenting at the Raymond James 39th Annual Institutional Investors Conference Orlando, FL on Monday, March 5th at 2:15 PM Eastern. A live webcast of the Company's presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
